Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Fang W, Yang ZY, Chen TY, Shen XF, Zhang C. Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med. 2020;18(1):145.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, et al. Effectiveness of Neoadjuvant Chemotherapy for muscle-invasive bladder Cancer in the current Real World setting in the USA. Eur Urol Oncol. 2018;1(1):83–90.

Article  PubMed  Google Scholar 

Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2021. NCHS Data Brief. 2022(456):1–8.

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.

Article  CAS  PubMed  Google Scholar 

Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder Cancer: Summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104.

Article  CAS  PubMed  Google Scholar 

Hamid A, Ridwan FR, Parikesit D, Widia F, Mochtar CA, Umbas R. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol. 2020;20(1):158.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for muscle-invasive bladder Cancer: a systematic review and two-step Meta-analysis. Oncologist. 2016;21(6):708–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171–7.

Article  CAS  PubMed  Google Scholar 

Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kübler H, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36(2):43–53.

Article  PubMed  Google Scholar 

Posielski N, Koenig H, Ho O, Porter C, Flores JP. Use of Neoadjuvant Chemotherapy in Elderly patients with muscle-invasive bladder Cancer: a Population-based study, 2006–2017. Oncol (Williston Park). 2022;36(1):21–33.

Google Scholar 

Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.

Article  PubMed  PubMed Central  Google Scholar 

Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, et al. Using the National Cancer Database for Outcomes Research: a review. JAMA Oncol. 2017;3(12):1722–8.

Article  PubMed  Google Scholar 

McFerrin C, Davaro F, May A, Raza S, Siddiqui S, Hamilton Z. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer. Investig Clin Urol. 2020;61(6):565–72.

Article  PubMed  PubMed Central  Google Scholar 

Macleod LC, Yabes JG, Yu M, Fam MM, Hale NE, Turner RM 2, et al. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2019;37(7):462–9.

Mazzone E, Knipper S, Mistretta FA, Tian Z, Preisser F, Gallina A, et al. Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis? Cancer Epidemiol. 2019;58:83–8.

Article  PubMed  Google Scholar 

Nitta M, Kuroda S, Nagao K, Higure T, Zakoji H, Miyakita H, et al. Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study. Jpn J Clin Oncol. 2020;50(1):73–9.

Article  PubMed  Google Scholar 

Kubota M, Kanno T, Inoue T, Yamasaki T, Okumura K, Ito K, et al. Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: a matched-pair analysis in a multicenter cohort. Int J Urol. 2021;28(6):656–64.

Article  CAS  PubMed  Google Scholar 

Møller CT, Støer NC, Blindheim A, Berge V, Tafjord G, Fosså SD, et al. Downstaging and survival after neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study. BMC Cancer. 2022;22(1):1301.

Article  PubMed  PubMed Central  Google Scholar 

van Ginkel N, Hermans TJN, Meijer D, Boormans JL, Voortman J, Mertens L, et al. Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study. Int Urol Nephrol. 2022;54(12):3145–52.

Article  PubMed  PubMed Central  Google Scholar 

Russell B, Sherif A, Häggström C, Josephs D, Kumar P, Malmström PU, et al. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. Scand J Urol. 2019;53(4):206–12.

Article  PubMed  Google Scholar 

Soria F, Black PC, Fairey AS, Cookson MS, Yu EY, Kassouf W, et al. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU Int. 2021;128(1):79–87.

Article  CAS  PubMed  Google Scholar 

Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, et al. Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival. World J Urol. 2021;39(12):4363–71.

Article  PubMed  Google Scholar 

Marcq G, Afferi L, Neuzillet Y, Nykopp T, Voskuilen CS, Furrer MA et al. Oncological outcomes for patients harboring positive Surgical margins following radical cystectomy for muscle-invasive bladder Cancer: a Retrospective Multicentric Study on Behalf of the YAU Urothelial Group. Cancers (Basel). 2022;14(23).

Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, et al. Neoadjuvant Chemotherapy in Elderly patients with bladder Cancer: oncologic outcomes from a single Institution experience. Clin Genitourin Cancer. 2017;15(4):e583–9.

Article  PubMed  PubMed Central  Google Scholar 

Chau C, Wheater M, Geldart T, Crabb SJ. Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients. Eur J Cancer Care (Engl). 2015;24(2):155–62.

Article  CAS  PubMed  Google Scholar 

Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis DJ, Braaf L, et al. Assessment of Predictive genomic biomarkers for response to cisplatin-based Neoadjuvant Chemotherapy in bladder Cancer. Eur Urol. 2023;83(4):313–7.

Article  CAS  PubMed  Google Scholar 

Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, et al. Updated results of PURE-01 with preliminary activity of Neoadjuvant Pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(4):439–46.

Article  CAS  PubMed  Google Scholar